US court rules abortion pill restrictions unlawful

A federal court in Virginia has declared restrictions on the abortion pill mifepristone, implemented by the U.S. drug regulator, as unlawful. The court mandated the Trump administration to re-evaluate these rules, which have been a point of contention for abortion rights advocates.

The lawsuit was filed in May 2023 by the Center for Reproductive Rights on behalf of abortion providers in Virginia, Kansas, and Montana. The core of the dispute centered on the Risk Evaluation and Mitigation Strategy (REMS), a set of regulations that advocates argue create undue burdens. These include requirements for prescribers to register with the manufacturer, potentially creating a national database, and for pharmacies to obtain special certification and maintain detailed records. Additionally, a rule requiring patients to review counseling materials was criticized as inaccurate.

“

the new restrictions were “arbitrary and capricious” because “the FDA has steadfastly found, over the past quarter century, that mifepristone is a safe and effective medication.”

In his ruling, Judge Robert S. Ballou stated that the new restrictions were "arbitrary and capricious." He noted that the FDA has consistently affirmed mifepristone's safety and effectiveness over the past 25 years. The judge ordered the Trump administration to reconsider the rules but did not invalidate them entirely, nor did he find the FDA's principle of imposing safety restrictions to be illegal.

"This ruling is a win for science," commented Nancy Northup, CEO at the Center for Reproductive Rights. This case is distinct from another legal battle in the Fifth Circuit, where Louisiana is seeking to reinstate a ban on patients receiving mifepristone by mail or through pharmacies following a virtual consultation. The U.S. Supreme Court had temporarily allowed continued mail access to mifepristone, pending further review by the Fifth Circuit court.

“

This ruling is a win for science.